Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
add, care, central, chain, commodity, conflict, content, delay, delaying, deprioritizing, economic, effort, energy, Europe, evolve, fight, Foundation, fuel, geopolitical, global, globally, GOG, headcount, heightened, high, instability, invasion, key, leaving, led, magnify, median, Medicine, monotherapy, negotiated, nivolizumab, ORR, pandemic, partnered, pausing, pembrolizumab, Pending, persist, platinum, political, pound, prioritisation, profile, prolonged, recently, Regenerative, resistant, responding, restructure, restructuring, RMAT, rolling, runway, Russia, shortly, signalled, skilled, speed, standard, stop, stopped, stopping, summarised, thereof, TIL, transfer, Ukraine, uncertainty, urothelial, volatility, work, world
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view